Clinical Trial Update: A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) [Phase 3]

View source ↗

Summary

Phase 3 LATITUDE-TIMI 60 trial update evaluating whether losmapimod reduces major adverse cardiovascular events in acute coronary syndrome compared with placebo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acute Coronary Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2017-06-02